Search research articles
Contact Us
Filters
Showing results (221-230 of 278) with videos related to
Page
of 28
Sort By:
ACS Medicinal Chemistry Letters
|
May 14, 2025
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
Joanna L Chen, Joey L Methot, Matthew J Mitcheltree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2024
Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Aparna R Parikh, Bryant H Chee, Jill Tsai, et al.
Cancer Discovery
|
April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka, Jessica J Lin, Chendi Li, et al.
The Veterinary Record
|
May 20, 1998
Staffing at veterinary schools
S M Rhind, C L Scudamore, R E Clutton, et al.
JAMA Network Open
|
November 17, 2023
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer
Joy X Jarnagin, Anurag Saraf, Islam Baiev, et al.
Cancer Research Communications
|
January 30, 2026
Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Nussara Pakvisal, Leontios Pappas, Bennett A Caughey, et al.
NPJ Precision Oncology
|
August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Cancer Discovery
|
December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Anthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Discovery
|
December 9, 2015
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo, Giulia Siravegna, Lawrence S Blaszkowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 278) with videos related to
Sort By:
Page
of 28
ACS Medicinal Chemistry Letters
|
May 14, 2025
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1
Joanna L Chen, Joey L Methot, Matthew J Mitcheltree, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2024
Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Aparna R Parikh, Bryant H Chee, Jill Tsai, et al.
Cancer Discovery
|
April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Noritaka Tanaka, Jessica J Lin, Chendi Li, et al.
The Veterinary Record
|
May 20, 1998
Staffing at veterinary schools
S M Rhind, C L Scudamore, R E Clutton, et al.
JAMA Network Open
|
November 17, 2023
Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer
Joy X Jarnagin, Anurag Saraf, Islam Baiev, et al.
Cancer Research Communications
|
January 30, 2026
Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Nussara Pakvisal, Leontios Pappas, Bennett A Caughey, et al.
NPJ Precision Oncology
|
August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Cancer Discovery
|
December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Anthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Discovery
|
December 9, 2015
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo, Giulia Siravegna, Lawrence S Blaszkowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Page
of 28